Scarica l'app Stockscreener
48.19
1.69%
0.80
Dopo l'orario di chiusura:
48.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$47.39
Aprire:
$46.95
Volume 24 ore:
1.05M
Relative Volume:
1.22
Capitalizzazione di mercato:
$3.56B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-8.1128
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+6.90%
1M Prestazione:
-15.66%
6M Prestazione:
+25.36%
1 anno Prestazione:
+90.32%
Intervallo 1D:
$46.71
$49.41
Intervallo di 1 settimana:
$44.42
$49.41
Portata 52W:
$24.00
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
48.19 | 3.56B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Alpha DNA Investment Management LLC Buys Shares of 10,258 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
XTX Topco Ltd Purchases New Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Projected to Post Earnings on Tuesday - MarketBeat
Jump Financial LLC Buys New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Trading Up 6.8%What's Next? - MarketBeat
Lobbying Update: $20,000 of PTC THERAPEUTICS lobbying was just disclosed - Nasdaq
Walleye Capital LLC Invests $4.97 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Federated Hermes Inc. Purchases New Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million - Quantisnow
Russell Investments Group Ltd. Sells 61,542 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Renaissance Technologies LLC Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results - Quantisnow
MELAS Syndrome Therapeutics Market Size in 7MM is expected - openPR.com
PTC Therapeutics (PTCT) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results | PTCT Stock News - GuruFocus
PTC Therapeutics Reveals Q1 2025 Earnings Date: Key Financial Updates Coming May 6 - Stock Titan
Cautious Hold Rating for PTC Therapeutics Amidst FDA Reviews and Revenue Uncertainties - TipRanks
Alliancebernstein L.P. Buys 139,596 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
ADAR1 Capital Management LLC Purchases 28,023 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
American Century Companies Inc. Has $2.72 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results - marketscreener.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Headlands Technologies LLC - MarketBeat
Lee Scott Golden Sells 897 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Leigh Syndrome Treatment Market Set to Witness Significant - openPR.com
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Vanguard Group Inc. - MarketBeat
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Business And Shares Still Trailing The Industry - simplywall.st
Wellington Management Group LLP Decreases Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Trexquant Investment LP Has $14.15 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Thrivent Financial for Lutherans - MarketBeat
14,300 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by KLP Kapitalforvaltning AS - MarketBeat
Ptc Therapeutics’ chief medical officer sells shares worth $42,114 By Investing.com - Investing.com Australia
Ptc Therapeutics’ chief medical officer sells shares worth $42,114 - Investing.com
PTC Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
PTC Therapeutics (NASDAQ:PTCT) Shares Down 8.8% Following Analyst Downgrade - MarketBeat
Pictet Asset Management Holding SA Buys 381,319 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Given New $75.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):